Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 533 Squamous Cell Carcinoma of Head and Neck 274 Head and Neck Neoplasms 253 Lung Neoplasms 238 Uterine Cervical Neoplasms 178 Stomach Neoplasms 168 Esophageal Neoplasms 160 Nasopharyngeal Carcinoma 123 Urinary Bladder Neoplasms 116 Esophageal Squamous Cell Carcinoma 115 Neoplasms 113 Small Cell Lung Carcinoma 104 Breast Neoplasms 92 Neoplasm Metastasis 90 Ovarian Neoplasms 89 Cholangiocarcinoma 76 Carcinoma, Squamous Cell 76 Pancreatic Neoplasms 72 Biliary Tract Neoplasms 70 Mesothelioma, Malignant 57 Oropharyngeal Neoplasms 56 Carcinoma 55 Adenocarcinoma Of Esophagus 52 Recurrence 47 Parkinson Disease 4, Autosomal Dominant Lewy Body 47 Carcinoma, Ovarian Epithelial 45 Nasopharyngeal Neoplasms 41 Lymphoma 41 Adenocarcinoma of Lung 41 Triple Negative Breast Neoplasms 38

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Cisplatin × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡